AIDX logo

20/20 BIOLABS INC

AIDXNASDAQ
🏆 #5119 by market capUS Equity
$0.26▲ $0.02 (+10.84%)
Market closed · at close
🔔
Track AIDX
Get earnings, price moves & breaking news on Telegram
Track
24h▲ 10.8%
7d▼ 3.0%
14d▼ 19.0%
30d▼ 38.5%
ytd—
1y—
🏦Market Cap
$3M
Small Cap
📈Revenue Growth (YoY)
—
📊Gross Margin
31.5%
Moderate
💵FCF Margin
—
⚖️P/S Ratio
1.4x
Cheap
Otter Score
—
Insufficient data

Trading Snapshot

Day Range
$0.26 – $0.26
52-Week Range
$0.23 – $50.00
Volume (shares)
300
Avg Volume (shares)
—
Shares Outstanding
13.4M
Next Earnings
—

Fundamentals Snapshot

Annual Revenue
$2M
Last Q Revenue
$730,571
P/E Ratio
—
P/S Ratio
1.4x
EPS (TTM)
$-0.93
Dividend Yield
—
Dilution (1yr)
+116.3%
AIDX logo

20/20 BIOLABS INC

AIDX
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$2M▲ +16.7% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
29.6%▲ +43.8% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$3M▼ −41.2% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$1.9B▲ +73770.0% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
10.4M▲ +116.3% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
−$258M▼ −$258M YoY
StockOtter · stockotter.space

About 20/20 BIOLABS INC

20/20 GeneSystems, Inc. operates as a clinical laboratory testing company focused on cancer screening and viral testing services. The company provides multi-cancer early detection blood testing, including a test called OneTest, and offers viral testing services such as rapid COVID-19 test kits, including the Assure COVID-19 IgG/IgM rapid test. It operates the Clinical Lab Innovation Axcelerator (CLIAx), a shared laboratory facility that supports diagnostic test developers in bringing products to the U.S. market. The company also delivers its cancer screening algorithm technology through a software as a service (SaaS) platform in partnership with healthcare providers and supports diagnostic startups by offering access to shared laboratory space and resources. The company was founded in 2000 and is based in Gaithersburg, Maryland.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)

Insufficient data for all five components.

💎Quality★★★★★
⚖️Valuation★★★★★
💧Dilution★★★★★
Overall Score
Insufficient data
—/100

Analyst Ratings

ⓘ
Consensus
Buy
7 analysts
Strong Buy2
Buy4
Hold1
Sell0
Strong Sell0
Ratings as of Oct 2026

Latest News & Updates

News unavailable.